ARCT Q2 2023 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-61.2% YoY

Gross Profit

$7M64.4% margin

Operating Income

-$55M-526.4% margin

Net Income

-$53M-499.6% margin

EPS (Diluted)

$-1.98

QoQ Revenue Growth

-86.9%

Cash Flow

Operating Cash Flow

$51M

Free Cash Flow

$50M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$431M

Total Liabilities

$145M

Stockholders' Equity

$285M

Cash & Equivalents

$323M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$27M	-61.2%
Gross Profit	$7M	-$11M	+161.1%
Operating Income	-$55M	-$22M	-150.7%
Net Income	-$53M	-$22M	-143.7%

Revenue Segments

Grant

$954,000100%